ONCO.US Onconetix Inc

Healthcare Biotechnology USA Stocks
3.21 USD
Close of Nov 15, 2026
2.76 1,610
Market cap
USD 2.15M
P/E
0.0x
P/B
0.16x
ROE
-
Dividend yield
19.04%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ONCO.US undervalued?

Graham number

The Graham number of Onconetix Inc cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Onconetix Inc fundamental analysis

No fundamental analysis for Onconetix Inc yet.

Onconetix Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Onconetix Inc

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commerci…

Full company profile